GCTK Glucotrack, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1506983 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY40.4%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-620.6%
ROA-272.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets216.5%
Debt / equity—
Current ratio0.46x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio4.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $9.81M | $9.50M | $4.70M | $1.97M | $1.81M |
| SG&A expense | $6.28M | $5.05M | $2.28M | $2.46M | $2.09M |
| Operating income | -$16.09M | -$14.55M | -$7.10M | -$4.43M | -$4.04M |
| Interest expense | — | $44,000 | — | — | — |
| Net income | -$19.39M | -$22.60M | -$7.10M | -$4.43M | -$4.07M |
| EBITDA | -$16.05M | -$14.51M | -$7.09M | -$4.41M | -$4.00M |
| EPS (basic) | 31.22 | 4,106.00 | 34.18 | 0.29 | 0.26 |
| EPS (diluted) | 31.22 | 4,106.00 | 34.18 | 0.29 | 0.26 |
| Weighted avg. shares (diluted) | 621,094 | 5,503 | 207,603 | 15.47M | 15.45B |
| Balance sheet | |||||
| Cash & equivalents | $7.38M | $5.62M | $4.49M | $2.31M | $6.11M |
| Inventory | — | — | — | — | $321,000 |
| Current assets | $7.67M | $5.77M | $4.87M | $2.38M | $6.11M |
| PP&E, net | $138,000 | $95,000 | $27,000 | $40,000 | $69,000 |
| Total assets | $7.84M | $5.93M | $4.91M | $2.44M | $6.26M |
| Current liabilities | $4.77M | $1.27M | $1.51M | $1.01M | $883,000 |
| Total liabilities | $5.01M | $18.93M | $1.71M | $1.21M | $1.11M |
| Shareholders' equity | $2.83M | -$13.00M | $3.20M | $1.23M | $5.16M |
| Shares outstanding | 910,688 | 13,409 | 208,914 | 15.50M | 15.47M |
| Cash flow statement | |||||
| Operating cash flow | -$15.24M | -$12.49M | -$6.56M | -$3.73M | -$3.77M |
| Capital expenditure | $96,000 | $104,000 | — | $1,000 | $5,000 |
| Free cash flow | -$15.34M | -$12.59M | — | -$3.73M | -$3.77M |
| Investing cash flow | -$96,000 | -$104,000 | — | $1,000 | -$1,000 |
| Financing cash flow | $17.04M | $13.74M | $8.73M | — | — |
| Depreciation & amortization | $42,000 | $36,000 | $13,000 | $23,000 | $42,000 |
| Stock-based compensation | $211,000 | $173,000 | $281,000 | $439,000 | $223,000 |
Free plan shows the latest 5 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.